As obesity rates soar, glucagon-like peptide-1 (GLP-1) receptor agonists are gaining traction for their potential to combat chronic diseases linked to obesity, with the market projected to exceed $160 billion by 2031. These drugs, while effective in weight loss and treating conditions like type 2 diabetes and sleep apnea, face challenges such as side effects and high costs that may hinder patient adherence. Despite these hurdles, the demand for innovative obesity treatments remains strong, presenting investment opportunities in specialized companies focused on improving existing therapies.